Free Trial

Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 5,000 Shares of Stock

Tempus AI logo with Medical background

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 5,000 shares of the business's stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief operating officer owned 145,000 shares of the company's stock, valued at approximately $8,700,000. The trade was a 3.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

  • On Tuesday, May 20th, Ryan Fukushima sold 7,820 shares of Tempus AI stock. The shares were sold at an average price of $63.21, for a total value of $494,302.20.
  • On Tuesday, May 6th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $52.36, for a total value of $1,047,200.00.

Tempus AI Stock Up 1.8%

Shares of TEM traded up $1.02 during trading hours on Thursday, reaching $59.43. The company's stock had a trading volume of 2,813,646 shares, compared to its average volume of 7,448,565. The firm has a market cap of $10.29 billion and a price-to-earnings ratio of -7.63. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $91.45. The company has a quick ratio of 1.56, a current ratio of 1.71 and a debt-to-equity ratio of 2.45. The company has a 50 day moving average of $62.83 and a two-hundred day moving average of $54.48.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. The firm had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The company's quarterly revenue was up 75.4% compared to the same quarter last year. As a group, research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TEM shares. Morgan Stanley upped their price objective on Tempus AI from $60.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Bank of America raised their target price on shares of Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 25th. Guggenheim raised their target price on shares of Tempus AI from $65.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. BTIG Research began coverage on shares of Tempus AI in a research report on Monday, April 21st. They set a "buy" rating and a $60.00 price target on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a research note on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Tempus AI currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.09.

Check Out Our Latest Analysis on TEM

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new position in shares of Tempus AI during the 4th quarter worth about $216,000. Wells Fargo & Company MN raised its stake in shares of Tempus AI by 13.2% during the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after purchasing an additional 278 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new position in shares of Tempus AI during the 1st quarter worth approximately $535,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 31.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after acquiring an additional 1,016,384 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Tempus AI in the 1st quarter valued at $1,019,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Recommended Stories

Insider Buying and Selling by Quarter for Tempus AI (NASDAQ:TEM)

Should You Invest $1,000 in Tempus AI Right Now?

Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines